Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc
Bullboard Posts
User Avatar Image
(31)
•••
Comment by stanleyon Nov 08, 2010 10:24pm
452 Views
Post# 17677907

RE:Charles Oliver BNN Top Pick. - Brigus Gold

RE:Charles Oliver BNN Top Pick. - Brigus GoldTerry:

[S] Finally Brigus gets a "TOP PICK" from Sprott on BNN:

1.  Looking at 90,000 AU OZS in 2010 (does that include the silver credits? LOL).

2.  Brigus resulted from a merger between Linear & Apollo Gold. i.e. a junior with a lot of debt and a hedge book combined with a junior with a well funded Linear.  Result is a reduction in debt to $20 mln and a significant reduction in the debt.

3. Goldfields (Box Mine in Sask) mentioned as the potential source of the ounces that would take Brigus to the 180,000 Au OZ level.  Why BRD at this stage? Because it is FULLY permitted.  The GF & PR are not that far along the NI 43-101 path. However, where/why did the 235 m level drift have to stop? I'm sure RA has enough Barrick experience to drive an exploration drift into PR and possibly GF from BF. 

4. "Revaluation - a question of time". 

BWDIK? Given time rejigging of development plans and sequencing might help WD under promise and over deliver. Can we expect to see a concerted promotional effort from Haywood & others as we move into $1400 POG? 

Cheers
Stanley
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities